FDA to expedite review of Pharmacyclics-Janssen's blood cancer drug

08/29/2013 | Manufacturing.net · American City Business Journals

Pharmacyclics obtained priority-review status from the FDA for its application to market ibrutinib as a treatment for previously treated mantle cell lymphoma and chronic lymphocytic leukemia. The application's acceptance triggers payment of a $75 million fee from partner Janssen Biotech.

View Full Article in:

Manufacturing.net · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC